The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · cited 2×
“These effector molecules include PLC-g1, Ras-MEK-MAPK, phosphatidylinositol-3 kinase (PI3K) and its target Akt, p70S6 kinase, Src, and STATs, among others (Olayioye et al., 2000; Yarden and Sliwkowski, 2001).”
BackgroundThe phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80595-4 · Cited by 5,594
Cellular survival: a play in three Akts
Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216
Vlahos, C. J., Matter, W. F., Hui, K. Y., & Brown, R. F. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37680-9 · Cited by 3,240
Olayioye, M. A. (2000) · The EMBO Journal · doi:10.1093/emboj/19.13.3159 · Cited by 2,434
Cantley, L. C., & Neel, B. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4240 · Cited by 2,006
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression
Yu, H. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.18.1472 · Cited by 1,424
PIK3CA is implicated as an oncogene in ovarian cancer
Shayesteh, L., Lu, Y., Kuo, W.-L., Baldocchi, R., Godfrey, T., Collins, C., Pinkel, D., Powell, B., Mills, G. B., & Gray, J. W. (1999) · Nature Genetics · doi:10.1038/5042 · Cited by 1,155
Self-citationZhou, B. P., Liao, Y., Xia, W., Spohn, B., Lee, M.-H., & Hung, M.-C. (2001) · Nature Cell Biology · doi:10.1038/35060032 · Cited by 1,135
HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation
Zhou, B. P., Liao, Y., Xia, W., Zou, Y., Spohn, B., & Hung, M.-C. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-973 · Cited by 951
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 882
Molecular alterations of the AKT 2 oncogene in ovarian and breast carcinomas
Bellacosa, A., De Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640412 · Cited by 837
Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D. G., Kaye, S. B., Gianni, L., Harris, A., Bjork, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.100 · Cited by 829
Sun, H., Lesche, R., Li, D.-M., Liliental, J., Zhang, H., Gao, J., Gavrilova, N., Mueller, B., Liu, X., & Wu, H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6199 · Cited by 796
Shin, I., Yakes, F. M., Rojo, F., Shin, N.-Y., Bakin, A. V., Baselga, J., & Arteaga, C. L. (2002) · Nature Medicine · doi:10.1038/nm759 · Cited by 790
Self-citationRanson, M., Hammond, L. A., Ferry, D., Kris, M., Tullo, A., Murray, P. I., Miller, V., Averbuch, S., Ochs, J., Morris, C., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.112 · Cited by 763
Chan, T. O., Rittenhouse, S. E., & Tsichlis, P. N. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.965 · Cited by 737
PTEN: Life as a Tumor Suppressor
Simpson, L., & Parsons, R. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5130 · Cited by 679
Prenzel, N., Fischer, O. M., Streit, S., Hart, S., & Ullrich, A. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080011 · Cited by 673
Mutational Spectra of PTEN/MMAC1 Gene: a Tumor Suppressor With Lipid Phosphatase Activity
Ali, I. U., Schriml, L. M., & Dean, M. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.22.1922 · Cited by 542
Li, D.-M., & Sun, H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15406 · Cited by 489
Nakatani, K., Thompson, D. A., Barthel, A., Sakaue, H., Liu, W., Weigel, R. J., & Roth, R. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.21528 · Cited by 475
Gschwind, A., Zwick, E., Prenzel, N., Leserer, M., & Ullrich, A. (2001) · Oncogene · doi:10.1038/sj.onc.1204192 · Cited by 462
Sun, M., Wang, G., Paciga, J. E., Feldman, R. I., Yuan, Z.-Q., Ma, X.-L., Shelley, S. A., Jove, R., Tsichlis, P. N., Nicosia, S. V., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61714-2 · Cited by 454
D'Cruz, C. M., Gunther, E. J., Boxer, R. B., Hartman, J. L., Sintasath, L., Moody, S. E., Cox, J. D., Ha, S. I., Belka, G. K., Golant, A., et al. (2001) · Nature Medicine · doi:10.1038/84691 · Cited by 418
Perren, A., Weng, L.-P., Boag, A. H., Ziebold, U., Thakore, K., Dahia, P. L. M., Komminoth, P., Lees, J. A., Mulligan, L. M., Mutter, G. L., et al. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65227-3 · Cited by 378
Rodrigues, G. A., Falasca, M., Zhang, Z., Ong, S. H., & Schlessinger, J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.4.1448-1459.2000 · Cited by 345
Lu, Y., Lin, Y.-Z., LaPushin, R., Cuevas, B., Fang, X., Yu, S. X., Davies, M. A., Khan, H., Furui, T., Mao, M., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1203183 · Cited by 322
Self-citationLane, H. A., Beuvink, I., Motoyama, A. B., Daly, J. M., Neve, R. M., & Hynes, N. E. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.9.3210-3223.2000 · Cited by 298
Forkhead transcription factors: new insights into protein kinase B (c-akt) signaling
Kops, G. J. P. L., & Burgering, B. M. T. (1999) · Journal of Molecular Medicine · doi:10.1007/s001099900050 · Cited by 283
Employment of the Epidermal Growth Factor Receptor in Growth Factor–Independent Signaling Pathways
Carpenter, G. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.146.4.697 · Cited by 272
Fedi, P., Pierce, J. H., di Fiore, P. P., & Kraus, M. H. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.1.492 · Cited by 228
Busse, D., Doughty, R. S., Ramsey, T. T., Russell, W. E., Price, J. O., Flanagan, W. M., Shawver, L. K., & Arteaga, C. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.10.6987 · Cited by 205
Self-citationMutation analysis of the PTEN/MMAC1 gene in lung cancer
Forgacs, E., Biesterveld, E. J., Sekido, Y., Fong, K., Muneer, S., Wistuba, I. I., Milchgrub, S., Brezinschek, R., Virmani, A., Gazdar, A. F., et al. (1998) · Oncogene · doi:10.1038/sj.onc.1202070 · Cited by 202
Shin, I., Bakin, A. V., Rodeck, U., Brunet, A., & Arteaga, C. L. (2001) · Molecular Biology of the Cell · doi:10.1091/mbc.12.11.3328 · Cited by 178
Self-citationPhosphoinositide 3-kinase signalling in breast cancer: how big a role might it play?
Fry, M. (2001) · Breast Cancer Research · doi:10.1186/bcr312 · Cited by 148
Inactivation of thePTEN/MMAC1/TEP1 gene in human lung cancers
Kohno, T., Takahashi, M., Manda, R., & Yokota, J. (1998) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199806)22:2<152::aid-gcc10>3.0.co;2-s · Cited by 147
Lenferink, A. E. G., Simpson, J. F., Shawver, L. K., Coffey, R. J., Forbes, J. T., & Arteaga, C. L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.160564197 · Cited by 124
Self-citationvan de Vijver, M. J., Kumar, R., & Mendelsohn, J. M. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)89475-7 · Cited by 122
Nelson, J. M., & Fry, D. W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008786200 · Cited by 108
Hermanto, U., Zong, C., & Wang, L.-H. (2001) · Oncogene · doi:10.1038/sj.onc.1204964 · Cited by 65
Cited by
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058
Targeting PI3K/Akt signal transduction for cancer therapy
He, Y., Sun, M. M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 1,892
Metadata
- Authors
- Bianco, R., Shin, I., Ritter, C. A., Yakes, F. M., Basso, A., Rosen, N., Tsurutani, J., Dennis, P. A., Mills, G. B., & Arteaga, C. L.
- Venue
- Oncogene
- Published
- 2003-05-08
- Volume
- 22
- Issue
- 18
- Pages
- 2812-2822
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1978916359
- Cited by
- 448
- References
- 43
- FWCI
- 19.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.